Overview

A Study of JNJ-87890387 for Advanced Solid Tumors

Status:
Recruiting

Trial end date:
2026-09-11

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine recommended phase 2 dose(s) (RP2Ds) of JNJ-87890387 and to determine the safety of JNJ-87890387 at the RP2D(s).

Phase:

Phase 1

Details

Lead Sponsor:

Janssen Research & Development, LLC